Multinational clinical trials offer foreign pharmaceutical companies the opportunity to bring innovative treatments to a broader patient population. However, expanding the research footprint also brings the complex requirement of complying with diverse international regulations.
The loss of investigational products (IP) during a clinical trial severely influences the clinical trial’s integrity, participant safety, and regulatory compliance. When the absence of IPs is noticed during a clinical study, implementing the necessary measures by Sponsors in a timely manner is of great importance.
